License agreement for development and sales of new anti-ulcerant

Published: 2010-04-28 06:59:00

Updated: 2010-04-28 06:59:00

Choong-wae Pharm concluded a license agreement with Mitsubishi Tanabe Pharma on April 26, granting Choong-wae exclusive rights in Korea for the development and sale of S-Tenatoprazole-Na (STU-Na), a new drug currently under clinical development, belongs to a class of drugs, called proton pump inh...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK